A study to investigate how a new drug, CHF10067, affects the body for people with IPF

Upcoming study
Expected to open January 2023
This study is currently recruiting
Expected to close June 2024
This study is closed
This study closed in June 2024
We will update this page with study results when available.
Information on study results are included below
This study closed in June 2024
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

This study is finding out how a new drug, CHF10067, might affect people with IPF. The drug is a monoclonal antibody (MAB), which recognises and finds proteins on specific cells and help the immune system. Some patients who take part will be given the study drug and some will not.

The researchers want to learn how the new drug affects the body when it is given to people with IPF.

The study will learn about any side effects of the drug and understand how people respond to it.  


What is involved?

You will be given either a single dose of a new drug, CHF10067, or a lookalike drug (placebo). The placebo does not contain the active medicine and instead will just contains fluids. Patients who are given the new drug will be receive a low, medium or higher dose. The drug or the placebo will be given to you through an intravenous drip. This will happen just once during the study. People who take part will be monitored before receiving the treatment, through to the end of the study at day 84.

Summary of involvement

Participation for up to 84 days

Single intravenous dose of either the new drug or a placebo

Monitoring of how the body responds to the drug through medical assessments and blood tests

Lung function tests & heart monitoring

Can I take part?

You may be able to take part if you have a confirmed diagnosis of IPF and are aged between 40 and 80 years.

You can be taking antifibrotic medication (nintedanib or pirfenidone) if your treatment has been stable for 8 weeks. You can also take part if you are not taking antifibrotics.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Aged between 40 and 80 years

Body weight greater than 45 kg

Diagnosis of IPF within the past 5 years


Not receiving antifibrotic treatment


Stable and well tolerated antifibrotic treatment

There is also a criteria for lung function, but this must be discussed with the research team

You will not be able to join the study of any of the following applies:

Respiratory infection within the last 2 months

An acute exacerbation within the last 3 months

Current diagnosis of lung cancer or any other form of cancer within the last 5 years

Current wound healing or foot ulcer complications

Current heart failure or severe pulmonary hypertension

Pregnant or breastfeeding women

Currently taking or have taken, corticosteroids, immunosuppressants, cytotoxic therapy, or vasodilator therapy for pulmonary hypertension within the last 4 weeks

Received investigational or unapproved treatment for IPF within the last 4 weeks

What difference could taking part make?

People affected by IPF currently have limited treatment options to slow the progression of disease. New research, such as this study, is needed to gain valuable knowledge about potentially better treatment options.

Taking part in this study would help researchers to understand the effects of the new drug when given to people with IPF. The study will help to gain understanding of which drug dose may be most suitable for future investigations in further research studies.

Where does the study take place?

Study locations







How to take part

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.


This study is supported by

Chiesi Farmaceutici S.p.A.
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org